1. Home
  2. LSAK vs RGNX Comparison

LSAK vs RGNX Comparison

Compare LSAK & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LSAK
  • RGNX
  • Stock Information
  • Founded
  • LSAK 1997
  • RGNX 2008
  • Country
  • LSAK South Africa
  • RGNX United States
  • Employees
  • LSAK N/A
  • RGNX N/A
  • Industry
  • LSAK Investment Bankers/Brokers/Service
  • RGNX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • LSAK Finance
  • RGNX Health Care
  • Exchange
  • LSAK Nasdaq
  • RGNX Nasdaq
  • Market Cap
  • LSAK 404.8M
  • RGNX 372.1M
  • IPO Year
  • LSAK N/A
  • RGNX 2015
  • Fundamental
  • Price
  • LSAK $5.28
  • RGNX $7.37
  • Analyst Decision
  • LSAK
  • RGNX Strong Buy
  • Analyst Count
  • LSAK 0
  • RGNX 12
  • Target Price
  • LSAK N/A
  • RGNX $36.00
  • AVG Volume (30 Days)
  • LSAK 10.5K
  • RGNX 1.8M
  • Earning Date
  • LSAK 02-05-2025
  • RGNX 02-25-2025
  • Dividend Yield
  • LSAK N/A
  • RGNX N/A
  • EPS Growth
  • LSAK N/A
  • RGNX N/A
  • EPS
  • LSAK N/A
  • RGNX N/A
  • Revenue
  • LSAK $573,679,000.00
  • RGNX $84,327,000.00
  • Revenue This Year
  • LSAK $2.24
  • RGNX $2.92
  • Revenue Next Year
  • LSAK $15.72
  • RGNX $234.86
  • P/E Ratio
  • LSAK N/A
  • RGNX N/A
  • Revenue Growth
  • LSAK 6.38
  • RGNX N/A
  • 52 Week Low
  • LSAK $3.00
  • RGNX $6.56
  • 52 Week High
  • LSAK $5.60
  • RGNX $28.80
  • Technical
  • Relative Strength Index (RSI)
  • LSAK 52.32
  • RGNX 42.98
  • Support Level
  • LSAK $4.93
  • RGNX $6.98
  • Resistance Level
  • LSAK $5.33
  • RGNX $7.70
  • Average True Range (ATR)
  • LSAK 0.18
  • RGNX 0.57
  • MACD
  • LSAK -0.00
  • RGNX 0.02
  • Stochastic Oscillator
  • LSAK 53.42
  • RGNX 35.53

About LSAK Lesaka Technologies Inc.

Lesaka Technologies Inc provides payment solutions, transaction processing solutions, and financial technologies. The company operates two reportable segments: Merchant and Consumer. The company operates mainly within South Africa. The Merchant segment that derives majority revenue includes activities related to the provision of goods and services provided to corporate and other juristic entities. It earns fees from processing activities performed for its customers and revenue generated from the distribution of prepaid airtime. The Consumer segment includes activities related to the provision of financial services to customers, including bank accounts, loans, and insurance products. The firm charges monthly administration fees for all bank accounts.

About RGNX REGENXBIO Inc.

Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.

Share on Social Networks: